Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MabionWAR:MAB -0.64%25 EV-to-OCF is -3.67 as of Aug. 31, 2026. GuruFocus rates WAR:MAB with a GF Score™ of 25/100 and a GF Value™ of zł2.02 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,408 Biotechnology companies, Mabion ranks worse than 50.28% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Mabion's Enterprise Value is zł144.76 Mil.
Mabion's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was zł-39.49 Mil. Therefore, Mabion's EV-to-OCF for today is -3.67.
The historical rank and industry rank for Mabion's EV-to-OCF or its related term are showing as below:
WAR:MAB'
s EV-to-OCF Range Over the Past 10 Years
Min: -134.17 Med: -11.46 Max: 93.15
Current: -3.67
During the past 13 years, the highest EV-to-OCF of Mabion was 93.15. The lowest was -134.17. And the median was -11.46.
WAR:MAB's EV-to-OCF is ranked worse than 50.28% of 1408
companies
in the Biotechnology industry
Industry Median: -3.72
vs WAR:MAB: -3.67
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-08-31), Mabion's stock price is zł7.80.
Mabion's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was zł-3.530. Therefore, Mabion's PE Ratio (TTM) for today is At Loss.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Mabion's share price for today is zł7.80.
Mabion's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł-3.530.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Mabion EV-to-OCF Related Terms
Mabion EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Mabion's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Mabion's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mabion EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mabion's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Mabion's EV-to-OCF falls into.
Mabion's current Enterprise Value is zł144.76 Mil.
Mabion's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł-39.49 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mabion (WAR:MAB) has a EV-to-OCF of -3.67 as of Aug. 31, 2026. According to the industry distribution chart, Mabion ranks #708 out of 1408 companies in the Biotechnology industry, placing it in the top 50.3%.
Is Mabion's EV-to-OCF too high?
Mabion's current EV-to-OCF is -3.67. Based on the distribution chart, Mabion ranks #708 out of 1408 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Mabion has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Mabion's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Mabion ranks #708 out of 1408 companies for EV-to-OCF. This places Mabion in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Mabion's current EV-to-OCF is -3.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mabion stock overvalued right now?
Based on GuruFocus' analysis, Mabion (WAR:MAB) is currently considered Significantly Overvalued. The stock's GF Value™ is zł2.02, compared to a current price of zł7.80 — trading 286.1% above its estimated fair value. The current EV-to-OCF is -3.67. Mabion's overall GF Score™ is 25/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Mabion (WAR:MAB), the current EV-to-OCF is -3.67 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mabion (WAR:MAB) Overvalued in 2026?
Based on GuruFocus' analysis, Mabion stock appears to be overvalued.
The current stock price of zł7.80 is trading 286.1% above its estimated GF Value™ of zł2.02.
GuruFocus considers Mabion to be Significantly Overvalued.
Key valuation signals for WAR:MAB:
EV-to-OCF: -3.67
GF Value™: zł2.02 vs. price of zł7.80 (286.1% above fair value)
No single metric tells the full story. See the WAR:MAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mabion SA is a Polish biotechnology company focused on developing and launching modern biotechnology drugs based on monoclonal antibody technology. The drugs developed by the company are targeted treatments, characterized by the drug's ability to recognize the factor causing cancer and interact with this factor only. The company is working on the development of its main priority drug, referred to as the MabionCD20 drug. The therapeutic uses of MabionCD20 are for Non-Hodgkin's lymphoma, Leukemia, and Rheumatoid Arthritis.
25GF Score
Get the complete analysis for WAR:MAB
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:MAB has been successfully added to your 
